Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy. A Randomized Clinical Trial

Ophthalmology

Volumn 115, Issue 11, 2008, Pages 1938-1943

  Ahmadieh, Hamid ^a   Feghhi, Mostafa ^a   Tabatabaei, Homa ^a   Shoeibi, Nasser ^a   Ramezani, Alireza ^a   Mohebbi, Mohammad Reza ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

SILICONE OIL; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CILIARY DISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETINA DETACHMENT; RETINOTOMY; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY; VITREORETINOPATHY;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL DETACHMENT; SILICONE OILS; TRIAMCINOLONE ACETONIDE; VITRECTOMY; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 55049109486     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2008.05.016     Document Type: Article

References (31)

1. Silicone Study Group. Proliferative vitreoretinopathy. Am J Ophthalmol 99 (1985) 593-595
2. Lewis H., and Aaberg T.M. Causes of failure after repeat vitreoretinal surgery for recurrent proliferative vitreoretinopathy. Am J Ophthalmol 111 (1991) 15-19
3. Tano Y., Chandler D., and Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 90 (1980) 810-816
4. Chandler D., Rozakis G., de Juan Jr. E., and Machemer R. The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Am J Ophthalmol 99 (1985) 686-690
5. Wiedemann P., Sorgente N., Bekhor C., et al. Daunomycin in the treatment of experimental proliferative vitreoretinopathy: effective doses in vitro and in vivo. Invest Ophthalmol Vis Sci 26 (1985) 719-725
6. Chandler D.B., Hida T., Sheta S., et al. Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment. Graefes Arch Clin Exp Ophthalmol 225 (1987) 259-265
7. Khawly J.A., Saloupis P., Hatchell D.L., and Machemer R. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 229 (1991) 464-467
8. Hui Y.N., and Hu D. Prevention of experimental proliferative vitreoretinopathy with daunomycin and triamcinolone based on the time course of the disease. Graefes Arch Clin Exp Ophthalmol 237 (1999) 601-605
9. Rubsamen P.E., and Cousins S.W. Therapeutic effect of periocular corticosteroids in experimental proliferative vitreoretinopathy. Retina 17 (1997) 44-50
10. Rubsamen P.E., Davis P.A., Hernandez E., et al. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch Ophthalmol 112 (1994) 407-413
11. Berger A.S., Cheng C.K., Pearson P.A., et al. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis 37 (1996) 2318-2325
12. Yang C.S., Khawly J.A., Hainsworth D.P., et al. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol 116 (1998) 69-77
13. Ando N., Sen H.A., Berkowitz B.A., et al. Localization and quantitation of blood-retinal barrier breakdown in experimental proliferative vitreoretinopathy. Arch Ophthalmol 112 (1994) 117-122
14. Jonas J.B., Hayler J.K., and Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 84 (2000) 1064-1067
15. Cheema R.A., Peyman G.A., Fang T., et al. Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging 38 (2007) 365-370
16. Ryan S.J. The pathophysiology of proliferative vitreoretinopathy in its management. Am J Ophthalmol 100 (1985) 188-193
17. McCuen B.W., Landers M.B., and Machemer R. The use of silicone oil following failed vitrectomy for retinal detachment with advanced proliferative vitreoretinopathy. Graefes Arch Cin Exp Ophthalmol 224 (1986) 38-39
18. Arroyo M.H., Refojo M.F., Araiz J.J., et al. Silicone oil as a delivery vehicle for BCNU in rabbit proliferative vitreoretinopathy. Retina 13 (1993) 245-250
19. Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study report 2. Arch Ophthalmol 110 (1992) 780-792
20. Nakagawa M., Refojo M.F., Marin J.F., et al. Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 36 (1995) 2388-2395
21. Kivilcim M., Peyman G.A., El-Dessouky E.S., et al. Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic Surg Lasers 31 (2000) 474-478
22. Abrams G.W., Azen S.P., McCuen II B.W., et al. Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow up: Silicone Study report 11. Arch Ophthalmol 115 (1997) 335-344
23. Munir W.M., Pulido J.S., Sharma M.C., and Buerk B.M. Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol 40 (2005) 598-604
24. Gillies M.C., Simpson J.M., Luo W., et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 121 (2003) 667-673
25. Dehghan M.H., Ahmadieh H., Ramezani A.R., et al. A randomized, placebo-controlled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema. Int Ophthalmol 28 (2008) 7-17
26. Jonas J.B., Akkoyun I., Budde W.M., et al. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 122 (2004) 218-222
27. Perkins S.L., Gallemore R.P., Yang C.H., et al. Pharmacokinetics of the fluocinolone/5-fluorouracil codrug in the gas-filled eye. Retina 20 (2000) 514-519
28. Jonas J.B. Concentration of intravitreally injected triamcinolone acetonide in intraocular silicone oil. Br J Ophthalmol 86 (2002) 1450-1451
29. Beer P.M., Barkri S.J., Singh R.J., et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110 (2003) 681-686
30. Blumenkranz M.S., Claflin A., and Hajek A.S. Selection of therapeutic agents for intraocular proliferative disease: cell culture evaluation. Arch Ophthalmol 102 (1984) 598-604
31. Charteris D.G., Aylward G.W., Wong D., et al., PVR Study Group. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology 111 (2004) 2240-2245